These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 16100851)

  • 1. Appropriate indications for administration of tPA.
    Dachs R
    Am Fam Physician; 2005 Aug; 72(3):381; author reply 381-2. PubMed ID: 16100851
    [No Abstract]   [Full Text] [Related]  

  • 2. Acute ischemic stroke and new anticoagulants -- how to act in the acute phase of stroke?
    Marrone LC; Marrone AC
    Cerebrovasc Dis; 2013; 35(1):91. PubMed ID: 23429003
    [No Abstract]   [Full Text] [Related]  

  • 3. TPA for acute ischemic stroke.
    Fischer J
    S D J Med; 1997 Feb; 50(2):69-70. PubMed ID: 9062450
    [No Abstract]   [Full Text] [Related]  

  • 4. What if a patient with atrial fibrillation and anticoagulant treatment is suffering from acute ischemia stroke?
    Zhou C; Zhu L; Wu J; Fang S
    Cerebrovasc Dis; 2013; 35(1):89-90. PubMed ID: 23429002
    [No Abstract]   [Full Text] [Related]  

  • 5. Thrombolysis in an ischemic stroke patient on dabigatran anticoagulation: a case report.
    Marrone LC; Marrone AC
    Cerebrovasc Dis; 2012; 34(3):246-7. PubMed ID: 23018342
    [No Abstract]   [Full Text] [Related]  

  • 6. Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion.
    Coutts SB; Dubuc V; Mandzia J; Kenney C; Demchuk AM; Smith EE; Subramaniam S; Goyal M; Patil S; Menon BK; Barber PA; Dowlatshahi D; Field T; Asdaghi N; Camden MC; Hill MD;
    Stroke; 2015 Mar; 46(3):769-74. PubMed ID: 25677596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transient ischemic attack after tissue plasminogen activator: aborted stroke or unnecessary stroke therapy?
    Uchino K; Massaro L; Hammer MD
    Cerebrovasc Dis; 2010; 29(1):57-61. PubMed ID: 19893313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reasons for exclusion from thrombolytic therapy following acute ischemic stroke.
    Cocho D; Belvís R; Martí-Fàbregas J; Molina-Porcel L; Díaz-Manera J; Aleu A; Pagonabarraga J; García-Bargo D; Mauri A; Martí-Vilalta JL
    Neurology; 2005 Feb; 64(4):719-20. PubMed ID: 15728300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of acute ischemic stroke in very elderly patients: is intravenous thrombolysis beneficial?
    Sung PS; Chen CH; Hsieh HC; Fang CW; Hsieh CY; Sun YT; Hwang WJ
    Eur Neurol; 2011; 66(2):110-6. PubMed ID: 21849787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombolytic therapy for acute ischemic stroke after recent transient ischemic attack.
    Alonso de Leciñana M; Fuentes B; Masjuan J; Simal P; Díaz-Otero F; Reig G; Díez-Tejedor E; Gil-Nuñez A; Vivancos J; Egido JA
    Int J Stroke; 2012 Apr; 7(3):213-8. PubMed ID: 22098785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pro: intravenous tissue plasminogen activator in stroke patients with rapid, complete recovery during evaluation (transient ischemic attack) and evidence of middle cerebral artery occlusion.
    Köhrmann M; Schellinger PD
    Stroke; 2010 Dec; 41(12):3003-4. PubMed ID: 21030698
    [No Abstract]   [Full Text] [Related]  

  • 12. Stroke initiative speeds time of tPA administration.
    Rollins G
    Rep Med Guidel Outcomes Res; 2000 Jul; 11(15):5-7. PubMed ID: 11771566
    [No Abstract]   [Full Text] [Related]  

  • 13. Tissue plasminogen activator (tPA) for acute ischaemic stroke: why so much has been made of so little.
    Blacker DJ
    Med J Aust; 2004 Feb; 180(3):142-3; author reply 142-3. PubMed ID: 14748684
    [No Abstract]   [Full Text] [Related]  

  • 14. [The cutting-edge of medicine; new concept of TIA and changes in management of acute ischemic stroke].
    Minematsu K
    Nihon Naika Gakkai Zasshi; 2013 Mar; 102(3):731-7. PubMed ID: 23777168
    [No Abstract]   [Full Text] [Related]  

  • 15. Is hospitalization after TIA cost-effective on the basis of treatment with tPA?
    Nguyen-Huynh MN; Johnston SC
    Neurology; 2005 Dec; 65(11):1799-801. PubMed ID: 16344525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of off-label stroke treatment with tissue plasminogen activator.
    Kvistad CE; Logallo N; Thomassen L; Waje-Andreassen U; Brøgger J; Naess H
    Acta Neurol Scand; 2013 Jul; 128(1):48-53. PubMed ID: 23311439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The totaled health risks in vascular events (THRIVE) score predicts ischemic stroke outcomes independent of thrombolytic therapy in the NINDS tPA trial.
    Kamel H; Patel N; Rao VA; Cullen SP; Faigeles BS; Smith WS; Flint AC
    J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1111-6. PubMed ID: 23122722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Thrombolytic therapy with tPA for the treatment of acute stroke. The Standard Treatment with Alteplase to Reverse Stroke study].
    Di Pasquale G
    Ital Heart J Suppl; 2000 Jul; 1(7):947-8. PubMed ID: 10935744
    [No Abstract]   [Full Text] [Related]  

  • 19. Stroke center characteristics which influence the administration of thrombolytic therapy for acute ischemic stroke: a national survey of stroke centers in Taiwan.
    Jeng JS; Tang SC; Deng IC; Tsai LK; Yeh SJ; Yip PK
    J Neurol Sci; 2009 Jun; 281(1-2):24-7. PubMed ID: 19362319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality: the German Stroke Registers Study Group.
    Heuschmann PU; Berger K; Misselwitz B; Hermanek P; Leffmann C; Adelmann M; Buecker-Nott HJ; Rother J; Neundoerfer B; Kolominsky-Rabas PL; ;
    Stroke; 2003 May; 34(5):1106-13. PubMed ID: 12663875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.